Cassava Sciences halted its clinical trial for the Alzheimer's drug simufilam due to disappointing results showing no significant cognitive decline reduction.
The large-scale trial, involving over 1,900 participants with mild to moderate Alzheimer's, failed to meet its primary endpoint.
Many researchers questioned the trial's validity due to prior concerns about the drug's underlying science and data integrity issues.
This setback significantly impacts Cassava Sciences' future, as simufilam was their sole drug in advanced clinical trials, causing a substantial stock price drop.
